OrthoLogic/J&J's DePuy AcroMed
This article was originally published in The Gray Sheet
Executive SummaryJohnson & Johnson DePuy AcroMed subsidiary gains exclusive worldwide rights to sell OrthoLogic's SpinaLogic non-invasive lumbar stimulation device, which is used as an adjunctive treatment after lumbar spinal fusion to increase the probability of successful fusion. The ten-year agreement that began Aug. 18 is expected to advance SpinaLogic's presence in the domestic and international spinal market
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.